You are here

Novel Methodology for Identification of Senolytics that Reduce Age-related Disease and Dysfunction

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R44AG053131-02
Agency Tracking Number: R44AG053131
Amount: $1,391,082.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIA
Solicitation Number: PA15-269
Timeline
Solicitation Year: 2015
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-30
Award End Date (Contract End Date): 2021-05-31
Small Business Information
383 COLOROW DR
Salt Lake City, UT 84108-1201
United States
DUNS: 079240124
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 CHRISTOPHER GIBSON
 (801) 587-1629
 chris.gibson@recursionpharma.com
Business Contact
 CHRISTOPHER GIBSON
Phone: (801) 587-1629
Email: chris.gibson@recursionpharma.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): Chronic diseases of aging account for a significant proportion of healthcare spending and result in a painful and limiting existence for many tens of millions of Americans and hundreds of millions of people around the world. Recursion Pharmaceuticals has developed a drug discovery platform that re-purposes known drugs for the treatment of such diseases. The platform consists of high content fluorescent image analysis using machine-learning algorithms to identify relevant and on-target changes induced in human cells in which diseases and treatments have been modeled. This system has been adapted to screen for drugs which may preferentially destroy senescent cells, as this may result in improved tissue function and decreases in pathology and mortality related to aging. In this SBIR fast-track proposal we will:PHASE I Identify a morphological profile of senescence in a variety of human cell types. Progression to Phase II will depend on our ability to demonstrate the power of our morphological approach to identify senescent cells independent of any known senescent markers.PHASE II Identify known drugs which preferentially destroy senescent cells, without affecting healthy cells, as identified by morphometric means.Evaluate the efficacy of identified senolytic agents in a variety of tissue function and health-span models in mice. *Evaluate the effect of identified senolytic agents in a murine model of age-associated cardiovascular disease. Recursion Pharmaceuticals has the experience, tools, and drive to execute this Phase I/Phase II Fast-track SBIR proposal, and to accelerate commercial development of any compounds we identify as a result.PUBLIC HEALTH RELEVANCE: Chronic diseases of aging affect a significant proportion of Americans. Cellular senescence, a useful biological program which prevents replication of cells exposed to various stresses that may be at risk of initiating tumors, has long-term deleterious inflammatory effects. We will combine biological, imaging, and computational approaches to identify complex morphological profiles associated with senescence, to identify senescence- killing effects of known drugs, and to evaluate any hits in relevant models of aging.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government